The FDA accepted an application for a clinical development study on Dronabinol inhalation using Senzer’s inhaler device, a breath-activated inhaler.

The approval means the clinical program will begin to explore vomiting and chemotherapy-induced nausea in adult cancer patients who had suboptimal reactions to conventional antiemetics.

The program aims to validate how a pharmaceutical version of Dronabinol, an FDA-approved cannabinoid being developed by Insys, can be delivered through Senzer’s inhaler device.